var data={"title":"Clioquinol and hydrocortisone: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Clioquinol and hydrocortisone: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/7869?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=clioquinol-and-hydrocortisone-patient-drug-information\" class=\"drug drug_patient\">see &quot;Clioquinol and hydrocortisone: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23599973\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Ala-Quin;</li>\n      <li>Dermasorb AF</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2934288\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Vioform Hydrocortisone</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25498594\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antibiotic, Topical;</li>\n      <li>\n        Antifungal Agent, Topical;</li>\n      <li>\n        Corticosteroid, Topical</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23599605\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dermatologic disorders:</b> Topical: Apply a thin film 3 to 4 times daily.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Vioform Hydrocortisone [Canadian product]: Apply a thin film 2 to 3 times daily.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23599604\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Dermatologic disorders:</b> Children &ge;2 years and Adolescents: Refer to adult dosing</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23599606\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23599607\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23599608\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F243629\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cream, External: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ala-Quin: Clioquinol 3% and hydrocortisone 0.5% (28.4 g, 80 g)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dermasorb AF:  Clioquinol 3% and hydrocortisone 0.5% (30 g) [packaged in a kit with Dermasorb hydrating serum]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26320007\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US. Refer also to Dosage forms.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cream, External:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Vioform Hydrocortisone: Clioquinol 3% and hydrocortisone 1% (20 g, 50 g)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23599609\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">For external use only; avoid contact with eyes. Apply a thin film to clean, dry skin and rub in gently.  Can stain skin and fabric. Use of occlusive dressings is not recommended. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F243630\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Dermatologic disorders:</b> Acute and chronic dermatologic disorders including contact or atopic dermatitis; impetiginized eczema; nummular eczema; infantile eczema; endogenous chronic infectious dermatitis; stasis dermatitis; pyoderma; nuchal eczema and chronic eczematoid otitis externa; acne urticata; localized or disseminated neurodermatitis; lichen simplex chronicus; anogenital pruritus (vulvae, scroti, ani); folliculitis; bacterial dermatoses; mycotic dermatoses such as tinea (capitis, cruris, corporis, pedis); moniliasis; intertrigo.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23621382\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Reported with combination product; frequency not defined.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Allergic skin reaction, dyschromia, epidermal thinning, hair discoloration, skin rash</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Nonthrombocytopenic purpura</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F243632\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to iodochlorhydroxyquin, hydrocortisone, chloroxine, iodine, iodine-containing preparations, or related compounds; eye lesions; tuberculosis of the skin; herpes simplex, vaccinia, eczema vaccinia, varicella, or other viral infections of the skin.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in US labeling): Syphilitic skin infections; application to large areas, ulcerated areas, or to the eye; children &lt;2 years.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23598841\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Concerns related to adverse effects:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Adrenal suppression: Systemic absorption of topical corticosteroids may cause hypercortisolism or suppression of hypothalamic-pituitary-adrenal (HPA) axis, particularly in younger children or in patients receiving high doses for prolonged periods. HPA axis suppression may lead to adrenal crisis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Sensitization: Topical use has been associated with irritation (rare); discontinue use if irritation occurs.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Superinfection: Prolonged use may result in overgrowth of nonsusceptible organisms requiring appropriate therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Staining: May stain skin and fabrics; may discolor (yellowing) hair and fingernails (rare).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Systemic effects: Topical corticosteroids may be absorbed percutaneously. Absorption of topical corticosteroids may cause manifestations of Cushing syndrome, hyperglycemia, and/or glycosuria. Absorption is increased by the use of occlusive dressings, application to denuded skin, or application to large surface areas.</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disease-related concerns:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thyroid disease: Use caution in patients with thyroid disease.</p>\n    <p style=\"text-indent:0em;\">\n      <b>Special populations:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: Topical application poses a potential risk of toxicity to infants and children; striae has been reported with use of some corticosteroids in infants and children. Children may absorb proportionally larger amounts of corticosteroids after topical application and may be more prone to systemic effects. HPA axis suppression, intracranial hypertension, and Cushing syndrome have been reported in children receiving topical corticosteroids. Prolonged use may affect growth velocity; growth should be routinely monitored in pediatric patients.</p>\n    <p style=\"text-indent:0em;\">\n      <b>Other warnings/precautions:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate response: Re-evaluate patient if no response within 1 to 2 weeks.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Avoid use on large or eroded areas, use for &gt;1 week, and use of occlusive dressings.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23692651\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to individual components.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23692648\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=93382&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Aldesleukin: Corticosteroids may diminish the antineoplastic effect of Aldesleukin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ceritinib: Corticosteroids may enhance the hyperglycemic effect of Ceritinib. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Corticorelin: Corticosteroids may diminish the therapeutic effect of Corticorelin. Specifically, the plasma ACTH response to corticorelin may be blunted by recent or current corticosteroid therapy. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: Corticosteroids may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hyaluronidase: Corticosteroids may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving corticosteroids (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ritodrine: Corticosteroids may enhance the adverse/toxic effect of Ritodrine. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F243626\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23598838\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">Adverse events have been observed with corticosteroids in animal reproduction studies. Topical products are not recommended for extensive use, in large quantities, or for long periods of time in pregnant women (Reed, 1997).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23598840\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">Systemically administered corticosteroids are excreted in breast milk and endogenous hydrocortisone is also found in human milk. It is not known if systemic absorption following topical administration results in detectable quantities in human milk. Use with caution while breast-feeding; do not apply to nipples (Reed, 1997).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23599610\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">Observe affected area for increased irritation; growth in children.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23598845\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;margin-left:0em;\">Clioquinol is a broad spectrum antibacterial and antifungal agent; hydrocortisone is a corticosteroid that decreases inflammation by suppression of migration of polymorphonuclear leukocytes and reversal of increased capillary permeability.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23598847\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Topical corticosteroids are absorbed percutaneously. The extent is dependent on several factors, including epidermal integrity (intact vs abraded skin), formulation, and the use of occlusive dressings</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Hepatic</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine, bile</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23613358\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Cream</b> (Ala-Quin External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">3-0.5% (28.4 g): $509.83</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Kit</b> (Dermasorb AF External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">3-0.5% (142.4 g): $567.65</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5539786\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Cortoquinol (IN);</li>\n      <li>Hidrocorte (BR);</li>\n      <li>Hydroderm-C (SG);</li>\n      <li>Hydroform (AU);</li>\n      <li>Kalviocort (ID);</li>\n      <li>Vioform-Hydrocortisone (AE, BB, BH, BM, BS, BZ, CY, EG, GB, GY, IE, IL, IQ, IR, JM, JO, KW, LB, LY, NL, OM, QA, SA, SR, SY, TT, YE)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Ala-Quin (clioquinol and hydrocortisone). Johnson City, TN: Crown Laboratories Inc; October 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dermasorb AF (clioquinol and hydrocortisone) [prescribing information]. Johnson City, TN: Crown Laboratories Inc; November 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Reed, BR. Dermatologic Drugs, Pregnancy, and Lactation. A Conservative Guide. <i>Arch Dermatol</i>. 1997;133(7):894-898.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clioquinol-and-hydrocortisone-drug-information/abstract-text/9236528/pubmed\" target=\"_blank\" id=\"9236528\">9236528</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vioform Hydrocortisone (clioquinol and hydrocortisone). St-Laurent, Quebec, Canada: Paladin Labs Inc; January 2015.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 93382 Version 61.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F23599973\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F2934288\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F25498594\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F23599605\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F23599604\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F23599606\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F23599607\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F23599608\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F243629\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F26320007\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F23599609\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F243630\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F23621382\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F243632\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F23598841\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F23692651\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F23692648\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F243626\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F23598838\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F23598840\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F23599610\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F23598845\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F23598847\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F23613358\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F5539786\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/93382|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=clioquinol-and-hydrocortisone-patient-drug-information\" class=\"drug drug_patient\">Clioquinol and hydrocortisone: Patient drug information</a></li></ul></div></div>","javascript":null}